Recent Patents on CNS Drug Discovery

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078


Neurokinin 3 (NK3) Receptor Modulators for the Treatment of Psychiatric Disorders

Author(s): Paul W. Smith and Lee A. Dawson

Affiliation: Psychiatry CEDD, Glaxo SmithKline, New Frontiers Science Park (North), Harlow, Essex, CM19 5AW,UK.


The neurokinin-3 (NK3) is one of the tachykinin peptide neurotransmitter / neuromodulator receptor family. NK3 receptors are predominantly expressed in neurons of both the peripheral and central nervous systems and in particular, in many of the forebrain areas, such as frontal, parietal and cingulate cortices, and basal ganglia structures implicated in psychiatric disease states. Consistent with this localization pattern, NK3 receptors appear to modulate monoaminergic and amino acid neurotransmission within these structures. Taken together these observations have lead to the speculation that modulators of NK3 receptor activity may have therapeutic utility in psychiatric diseases such as schizophrenia and affective disorders. This speculation has recently gained clinical credence through a number of reports of efficacy in placebo controlled studies. In this article, the authors review the recent patent literature highlighting the various NK3 receptor modulation strategies for potential therapeutic utility in psychiatric disease indications.

Keywords: Tachykinins, neurokinin B, neurokinin 1, 2, 3 (NK1, NK2, NK3) receptors, schizophrenia, depression, panic, bipolar disorder, antagonist, modulator, agonist

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1 - 15]
Pages: 15
DOI: 10.2174/157488908783421447